Checkpoint Therapeutics Inc (CKPT)
$3.22
+0.21
(+6.98%)▲
Live
Performance
- $2.99$3.25$3.22
7.3%
Downside
Day's Volatility :8.13%
Upside
0.9%
- $1.36$3.62$3.22
57.76%
Downside
52 Weeks Volatility :62.43%
Upside
11.05%
Returns
| Period | Checkpoint Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 20.88% | 0.0% |
6 Months | 107.59% | 0.0% |
1 Year | 52.02% | 0.0% |
3 Years | -90.5% | -23.0% |
Highlights
Market Capitalization | 140.8M |
Book Value | -$0.37 |
Earnings Per Share (EPS) | -1.71 |
PEG Ratio | 0.0 |
Wall Street Target Price | 17.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -16275.61% |
Return On Assets TTM | -316.7% |
Return On Equity TTM | -1220.38% |
Revenue TTM | 78.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 32.300000000000004% |
Gross Profit TTM | -48.2M |
Diluted Eps TTM | -1.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.78 |
EPS Estimate Next Year | -0.18 |
EPS Estimate Current Quarter | -0.3 |
EPS Estimate Next Quarter | -0.29 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 427.95%
Technicals Summary
Sell
Neutral
Buy
Checkpoint Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Checkpoint Therapeutics Inc | 27.54% | 107.59% | 52.02% | -90.5% | -84.95% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Checkpoint Therapeutics Inc | NA | NA | 0.0 | -0.78 | -12.2 | -3.17 | NA | -0.37 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Checkpoint Therapeutics Inc | Buy | $140.8M | -84.95% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Checkpoint Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 6.0K → 41.0K (in $), with an average increase of 85.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -19.12M → -6.67M (in $), with an average increase of 69.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 43.5%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 135.3%
Institutional Holdings
Armistice Capital, LLC
5.57%Vanguard Group Inc
2.97%Geode Capital Management, LLC
0.67%National Asset Management Inc
0.51%BlackRock Inc
0.45%Legacy Wealth Asset Management, LLC
0.19%
Company Information
checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr
Organization | Checkpoint Therapeutics Inc |
Employees | 23 |
CEO | Mr. James F. Oliviero III, C.F.A. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.22
+6.98%
Invesco Bulletshares 2025 Hi
$3.22
+6.98%
Schwab International Dividend Equity Etf
$3.22
+6.98%
Blockchain Coinvestors Acquisition Corp.
$3.22
+6.98%
Allgiant Travel Company
$3.22
+6.98%
Rogers Corp
$3.22
+6.98%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.22
+6.98%
Iheartmedia
$3.22
+6.98%
Lightpath Technologies Inc
$3.22
+6.98%